Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Alessandro_Maselli
|
| gptkbp:formerName |
gptkb:Cardinal_Health_PTS
|
| gptkbp:founded |
2007
|
| gptkbp:headquartersLocation |
gptkb:Somerset,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Catalent
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:ISIN |
US1488061029
|
| gptkbp:notableAcquisition |
gptkb:MaSTherCell
gptkb:Paragon_Bioservices gptkb:R.P._Scherer |
| gptkbp:notableProduct |
gptkb:Zydis_fast-dissolve_technology
softgel technologies |
| gptkbp:numberOfEmployees |
~18,000
|
| gptkbp:parentCompany |
gptkb:Blackstone_(pending_acquisition,_2024)
|
| gptkbp:revenue |
$4.28 billion (2022)
|
| gptkbp:servesArea |
worldwide
|
| gptkbp:services |
drug delivery
drug development biologics manufacturing clinical supply services |
| gptkbp:stockExchange |
gptkb:NYSE
|
| gptkbp:stockSymbol |
gptkb:CTLT
|
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.catalent.com/
|
| gptkbp:bfsParent |
gptkb:AstraZeneca_COVID-19_vaccine
|
| gptkbp:bfsLayer |
5
|